Quarterly Activities Report and Appendix 4C
| Stock | Little Green Pharma Ltd (LGP.ASX) |
|---|---|
| Release Time | 30 Apr 2026, 9:37 a.m. |
| Price Sensitive | Yes |
Little Green Pharma Reports Record Quarterly and Annual Revenue
- Annual revenue of $42.4 million, up over 15% on prior year with a CAGR of 30% over the last four years
- Highest ever recorded quarterly revenue of $12.5 million, up over 15% on prior quarter
- Record quarterly European sales of $6.4 million, up over 70% on prior quarter
Little Green Pharma Ltd (ASX:LGP) reported its highest ever annual revenue of $42.4 million (unaudited), up over 15% on the prior year, with a compound annual growth rate of over 30% over the last four years. The company also recorded its highest ever quarterly revenue of $12.5 million, up over 15% on the prior quarter and nearly 30% on the prior corresponding quarter. This was driven by record quarterly European sales of $6.4 million, up over 70% on the prior quarter, including $5.5 million of sales into Germany. The company also reported its highest ever cash receipts of $13.3 million for the quarter, up over 20% on the prior quarter. LGP generated positive operating cashflows of $1.1 million, up from negative $1.0 million in the previous quarter, with minimal increase in operating costs despite the significant sales growth. The company also repaid $1.1 million of borrowings during the quarter, increasing its unused debt facilities to $5.6 million. The proposed merger between LGP and Cannatrek Ltd is progressing well, with shareholder approval of key conditions precedent and completion expected by 1 June 2026. Importantly, the US Justice Department has rescheduled medicinal cannabis from Schedule I to Schedule III under the Controlled Substances Act, which LGP believes will materially enhance the long-term prospects of the global medicinal cannabis sector.
Annual revenue of $42.4 million (unaudited), up over 15% on prior year. Quarterly revenue of $12.5 million (unaudited), up over 15% on prior quarter.
The proposed merger with Cannatrek is expected to provide synergy opportunities and accelerate the scaling of LGP's European operations, while the rescheduling of medicinal cannabis in the US is expected to enhance the long-term prospects of the global medicinal cannabis sector.